Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DWP712 vs Botox in Glabellar Lines
NCT07013279Phase 3Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Clostridium botulinum toxin type A (DWP712) in glabellar lines, sponsored by Daewoong Pharmaceutical. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
Clostridium botulinum toxin type A (DWP712)
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT07013279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013279.